Novo Nordisk Reports Results of Semaglutide from P-IIIa STEP 1 Trial in Patients with Obesity

Shots:

The company reported the results from the P-IIIa STEP 1 trial of the STEP programme assessing semaglutide (2.4 mg, SC, qw) vs PBO in adults with obesity for 68 wks. The results will be presented at ECO 2021
Results: The therapy showed 14.9% weight loss, 43.8% improvement in total weight-related QoL scores, 51.2% vs 32.9% participants improved weight-related physical function, 40% vs 27% participants achieved improvement in health-related physical functioning score, improved psychological well being
Semaglutide is an analogue of the human GLP-1 hormone, currently under investigation for chronic weight management and is under FDA and EMA’s review

Click here to read full press release/ article | Ref: PRNewswire | Image: Novo Nordisk